The National Cancer Institute (NCI) awarded a $545,170 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Versiti Wisconsin, Inc. to conduct research on therapeutic targeting of an oncogenic translational program in acute myeloid leukemia (AML) with the chromosome inversion inv(16). The grant aims to characterize the therapeutic potential of the small molecule inhibitor SBI-756, which targets the eukaryotic translation initiation factor 4 gamma 1 (EIF4G1), in overcoming drug resistance in inv(16) AML. The research will utilize a CBFB-SMMHC genetic mouse model and an inv(16) AML patient-derived xenograft model to evaluate SBI-756, as well as define the mechanisms of action of EIF4G1 in inv(16) AML. The project period runs from April 1, 2025 to March 31, 2030.
Generated 3/25/25, 3:45 AM